Search

Acetylcholine (ACh) is one of the main neuromodulators in the mammalian central nervous system (CNS). This chemical messenger has been implicated in the underlying physiology of many distinct cognitive functions. However, the exact role that ACh plays in regulating information processing in the brain is still not fully understood. The vesicular acetylcholine transporter (VAChT) is required for the storage of ACh into synaptic vesicles, and therefore it presents a means to modulate release. Diminished VAChT levels cause a decrease in cholinergic tone, whereas increased VAChT expression has been shown to augment ACh release. Previously published data have shown that elimination of VAChT in the basal forebrain in genetically-modified mice impairs learning and memory. For our studies we have used different mouse lines in which the expression of the VAChT gene is changed, both increased and decreased. We are therefore able to study the consequences of altered cholinergic tone in vivo. Our hypothesis is that changes in cholinergic tone produce specific molecular signatures in target brain areas that underlie alterations in cognitive function. Our studies aimed to elucidate the behavioural and molecular consequences of cholinergic dysfunction. Behavioral testing included classical learning and memory tests as well as sophisticated tasks using novel touch screens chambers to measure attention, learning and memory as well as cognitive flexibility. At the molecular level, the goal was to examine how long-term changes in cholinergic tone impact mechanisms regulating synaptic plasticity and neuronal health. Finally, by aging mouse models of cholinergic dysfunction we were able to elucidate the role that cholinergic tone plays in the classical pathological hallmarks of neurodegenerative disorders. Ultimately, by establishing the molecular signature of increased and decreased cholinergic tone in targeted brain regions (cortex and hippocampus) it may become possible to find novel targets for therapeutic interventions to improve cognitive deficits due to altered cholinergic tone.

Idiopathic Parkinson's Disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, which is associated with neuroinflammation and reactive gliosis. The underlying cause of PD and the concurrent neuroinflammation are not well understood. In this study, we utilized human and murine neuronal lines, stem cell-derived dopaminergic neurons, and mice to demonstrate that three previously identified genetic risk factors for PD, namely SATB1, MIR22HG, and GBA, are components of a single gene regulatory pathway. Our findings indicate that dysregulation of this pathway leads to the upregulation of glucocerebrosides (GluCer), which triggers a cellular senescence-like phenotype in dopaminergic neurons. Specifically, we discovered that downregulation of the transcriptional repressor SATB1 results in the derepression of the microRNA miR-22-3p, leading to decreased GBA expression and subsequent accumulation of GluCer. Furthermore, our results demonstrate that an increase in GluCer alone is sufficient to impair lysosomal and mitochondrial function, thereby inducing cellular senescence dependent on S100A9 and stress factors. Dysregulation of the SATB1-MIR22-GBA pathway, observed in both PD patients and normal aging, leads to lysosomal and mitochondrial dysfunction due to the GluCer accumulation, ultimately resulting in a cellular senescence-like phenotype in dopaminergic neurons. Therefore, our study highlights a novel pathway involving three genetic risk factors for PD and provides a potential mechanism for the senescence-induced neuroinflammation and reactive gliosis observed in both PD and normal aging.

Ongoing, first-in-human clinical trials illustrate the feasibility and translational potential of human pluripotent stem cell (hPSC)-based cell therapies in Parkinson's disease (PD). However, a major unresolved challenge in the field is the extensive cell death following transplantation with <10% of grafted dopamine neurons surviving. Here, we performed a pooled CRISPR/Cas9 screen to enhance survival of postmitotic dopamine neurons in vivo . We identified p53-mediated apoptotic cell death as major contributor to dopamine neuron loss and uncovered a causal link of TNFa-NFκB signaling in limiting cell survival. As a translationally applicable strategy to purify postmitotic dopamine neurons, we performed a cell surface marker screen that enabled purification without the need for genetic reporters. Combining cell sorting with adalimumab pretreatment, a clinically approved and widely used TNFa inhibitor, enabled efficient engraftment of postmitotic dopamine neurons leading to extensive re-innervation and functional recovery in a preclinical PD mouse model. Thus, transient TNFa inhibition presents a clinically relevant strategy to enhance survival and enable engraftment of postmitotic human PSC-derived dopamine neurons in PD., Highlights: In vivo CRISPR-Cas9 screen identifies p53 limiting survival of grafted human dopamine neurons. TNFα-NFκB pathway mediates p53-dependent human dopamine neuron deathCell surface marker screen to enrich human dopamine neurons for translational use. FDA approved TNF-alpha inhibitor rescues in vivo dopamine neuron survival with in vivo function.